Targeted failure of the week. Pos No 48. Revamilast.

Revamilast is an orally active, potent and selective inhibitor of phosphodiesterase 4 (PDE 4) that is currently being developed by Glenmark for the treatment of chronic inflammatory disorders such as asthma, rheumatoid arthritis (RA) and other inflammatory diseases. And you know? The drug failed:

 

Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) disclosed in its third quarter earnings for the fiscal year ending March 31, 2013, that revamilast missed the primary endpoint of improving ACR20 response rate at week 12 vs. placebo in a Phase IIb trial to treat rheumatoid arthritis (RA). The double-blind, international trial enrolled more than 400 RA patients. Glenmark said it is conducting additional analysis of the data, but said it is "unlikely" the company will continue development of revamilast in RA. Revamilast, a phosphodiesterase-4 (PDE-4) inhibitor, is also in Phase IIb testing to treat asthma.